Ideaya Biosciences (IDYA) disclosed last Friday that GSK (GSK) communicated to Ideaya its election to terminate the collaboration, option and license agreement. Pursuant to the terms of the agreement, such termination will be effective 90 days following the date of GSK’s written notice of December 4. During the ninety-day transition period, GSK will transfer the Werner Helicase and Pol Theta clinical programs to Ideaya. Ideaya said it will evaluate its strategic options for the two programs in 2026, and the update does not change its expectation of cash runway into 2030. Shares of Ideaya closed Monday down 1% to $35.34.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- IDEAYA Biosciences: Strategic Positioning and Promising Oncology Assets Drive Buy Rating
- GlaxoSmithKline Ends Collaboration with IDEAYA Biosciences
- Ideaya Biosciences announces FDA clearance of IDE034 IND application
- Ideaya Biosciences announces inducement grants under Nasdaq listing rule
- Ideaya Biosciences initiated with a Buy at Truist